Profile data is unavailable for this security.
About the company
OBio Technology Shanghai Corp Ltd is a China-based company mainly engaged in providing cell and gene therapy technology services. The Company is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development, gene function research, drug target and efficacy research for basic research of gene therapy, as well as contract development and manufacturing organization (CDMO) services for the research and development of cell and gene therapy drugs, such as process development and testing, investigational new drug application- chemistry manufacture and control (IND-CMC) pharmaceutical research, and good manufacturing practice (GMP) production of clinical samples and commercial products. The Company also provides technical services such as cell preparation, production of recombinant proteins/exosomes and other cell derivatives, and cell storage for the fields of regenerative medicine and anti-aging.
- Revenue in CNY (TTM)244.64m
- Net income in CNY-294.16m
- Incorporated2013
- Employees692.00
- LocationObio Technology Shanghai Corp Ltd908 Ziping RoadPudong New District, Building 19,SHANGHAI 201321ChinaCHN
- Phone+86 2 158050593
- Fax+86 2 155230588
- Websitehttps://www.obiosh.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Starry Pharmaceutical Co Ltd | 2.39bn | -29.25m | 4.61bn | 1.75k | -- | 1.77 | -- | 1.93 | -0.1149 | -0.1149 | 5.84 | 5.93 | 0.4078 | 1.78 | 5.62 | 1,363,012.00 | -0.4978 | 2.04 | -0.8498 | 3.75 | 18.98 | 27.73 | -1.22 | 5.05 | 0.4035 | 0.6728 | 0.5007 | 78.73 | 7.02 | 12.42 | -211.00 | -- | 29.24 | -3.43 |
| Yabao Pharmaceutical Group Co Ltd | 2.27bn | 222.85m | 4.66bn | 3.61k | 21.19 | 1.69 | -- | 2.05 | 0.3177 | 0.3177 | 3.26 | 3.99 | 0.6462 | 3.42 | 6.66 | 629,532.00 | 5.51 | 4.01 | 6.54 | 5.38 | 50.46 | 56.75 | 8.53 | 5.86 | 2.49 | -- | 0.0418 | 54.27 | -7.69 | -2.46 | 21.60 | 77.16 | -26.08 | 71.88 |
| Obio Technology Shanghai Corp Ltd | 244.64m | -294.16m | 4.69bn | 692.00 | -- | 3.08 | -- | 19.18 | -0.4578 | -0.4578 | 0.3819 | 2.35 | 0.1095 | 4.22 | 2.37 | 353,519.30 | -13.15 | -3.10 | -15.68 | -3.47 | -37.29 | 19.60 | -120.16 | -23.22 | 1.06 | -94.99 | 0.2068 | -- | 21.16 | 31.58 | -151.54 | -- | 36.17 | -- |
| Jinyao Pharmaceutical Co Ltd | 2.87bn | 16.30m | 4.71bn | 2.88k | 282.25 | 1.56 | -- | 1.64 | 0.0153 | 0.0153 | 2.63 | 2.77 | 0.49 | 2.45 | 6.38 | 996,743.00 | 1.39 | 1.87 | 2.18 | 3.31 | 41.43 | 45.67 | 2.84 | 3.30 | 1.19 | 11.91 | 0.1563 | 65.00 | -15.00 | -0.6786 | 14.01 | -3.78 | -23.40 | 19.63 |
| Ningbo Menovo Pharmaceutical Co Ltd | 1.54bn | 99.48m | 4.72bn | 2.47k | 47.53 | 2.04 | -- | 3.06 | 0.4502 | 0.4502 | 7.00 | 10.49 | 0.329 | 1.23 | 5.91 | 623,207.90 | 2.34 | 3.98 | 3.68 | 6.21 | 32.03 | 34.08 | 7.11 | 12.00 | 0.7165 | 5.71 | 0.3482 | 11.27 | 12.85 | 3.07 | 476.64 | -15.04 | -11.37 | -8.68 |
| Sinotherapeutics Inc | 480.48m | 98.59m | 4.74bn | 312.00 | 48.05 | 3.62 | -- | 9.86 | 0.2175 | 0.2175 | 1.06 | 2.89 | 0.333 | 2.74 | 4.51 | 1,539,987.00 | 6.83 | 10.22 | 7.32 | 11.26 | 43.78 | 65.76 | 20.52 | 31.88 | 11.08 | -- | 0.00002 | 13.77 | 70.61 | 29.80 | 109.09 | 94.07 | 32.01 | -- |
| Pulike Biological Engineering Inc | 1.10bn | 143.67m | 4.86bn | 1.55k | 33.40 | 1.88 | -- | 4.40 | 0.4204 | 0.4204 | 3.22 | 7.45 | 0.3571 | 2.68 | 3.03 | 711,690.80 | 4.65 | 6.79 | 5.41 | 8.00 | 57.65 | 62.55 | 13.02 | 16.34 | 2.51 | 15.83 | 0.0005 | 61.54 | -16.77 | 9.47 | -46.82 | -3.21 | 7.28 | 14.87 |
| Shanghai Xiao Fang Pharmaceutical Co Ltd | 504.59m | 213.50m | 4.87bn | 404.00 | 22.67 | 4.61 | -- | 9.64 | 1.33 | 1.33 | 3.16 | 6.57 | 0.3795 | 3.71 | 4.85 | 1,248,981.00 | 16.06 | -- | 19.02 | -- | 65.40 | -- | 42.31 | -- | 3.47 | -- | 0.0017 | -- | 0.5748 | -- | 0.8074 | -- | -- | -- |
| Tibet Weixinkang Pharmaceutical Co Ltd | 1.17bn | 222.08m | 4.97bn | 689.00 | 22.26 | 3.26 | -- | 4.26 | 0.5136 | 0.5136 | 2.71 | 3.51 | 0.608 | 11.75 | 6.71 | 1,695,637.00 | 11.56 | 10.05 | 14.30 | 13.45 | 58.42 | 51.50 | 19.01 | 13.72 | 3.93 | -- | 0.0058 | 52.31 | -1.69 | 11.90 | 15.02 | 34.62 | 5.91 | 50.02 |
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 1.67m | 0.39% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 1.11m | 0.26% |
| CCB Principal Asset Management Co., Ltd.as of 30 Jun 2025 | 747.55k | 0.17% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 722.33k | 0.17% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2025 | 666.33k | 0.15% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2025 | 560.10k | 0.13% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 409.00k | 0.10% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 336.58k | 0.08% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 212.03k | 0.05% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 118.05k | 0.03% |
